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Effect of patient’s sex on risk of recurrent venous thromboembolism: A
meta-analysis
McRae S, Tran H, Schulman S, et al. Lancet 2006;368:371-78.
Conclusion: Men have a 50% higher risk of recurrent venous throm-
boembolism (VTE) after cessation of anticoagulant therapy.
Summary: The authors performed a meta-analysis to examine the
question of risk of recurrent VTE in men versus women after cessation of
anticoagulation treatment. Eligible articles were identified using the Coch-
ran Database 2005, Issue 1, EM (1980 to February 2005) and MedLine
(Source Pub Med, 1996 to February 2005). To be included, a trial must
have been prospective and randomized. Patients were required to have
objectively diagnosed VTE. Treatment must have been for a minimum of 1
month, and there must have been follow-up for recurrence of VTE after
anticoagulant therapy was stopped. The authors analyzed study design,
study quality, and the sex, number, and age of enrolled patients as well as risk
factors for VTE. The treatment given, duration of followup, and number of
episodes of recurrent VTE was also analyzed.
Based on the data, the estimate of relative risk of recurrent VTE formen
compared with women was 1.6 (95% confidence interval [CI], 1.2 to 2.0).
The higher risk of recurrent VTE in males was consistent across predefined
subgroups. There was a higher risk of recurrence in males from observational
studies (relative risk 2.1; 95% CI 1.5 to 2.9) than in randomized trials
(relative risk 1.3; 95% CI, 1.0 to 1.8). A reduced rate of recurrence of VTE
in women after VTE associated with pregnancy or estrogen therapy did not
account for the differences between men and women.
Comment: This meta-analysis used strict inclusion criteria for studies
and analyzed large numbers of patients with predefined subgroups for
analysis. This lends strength to the authors’ conclusions. There was, how-
ever, heterogenicity among studies and differences among relative risks from
randomized trials vs observational studies. The trials did not have individual
patient data, and, therefore, a true multivariant analysis could not be done to
assess individual variables on study outcome. Nevertheless, the data argue
strongly for inclusion of sex as another variable in determining the length of
anticoagulant therapy following VTE.
Angiotensin-converting enzyme inhibitors and aortic rupture: A
population-based, case-controlled study
Hackam DJ, Thiruchelvam D, Redelmeier DA. Lancet 2006; 368:659-65.
Conclusion: Angiotensin-converting enzyme (ACE) inhibitors appear
to be associated with a reduced risk of ruptured abdominal aortic aneurysm
(AAA).
Summary: Studies in animal models indicate ACE inhibitors may
prevent expansion and rupture of aortic aneurysms. In this investigation,
ruptured AAA in humans was studied for association with ACE inhibitors.
This was a population-based, case-controlled study from April 1, 1992, to
April 1, 2002, using linked administrative databases from Ontario, Canada.
The study sample was 15,326 consecutive patients 65 years of age who
were admitted to a hospital with either intact or ruptured AAA as the primary
diagnosis.
Patients receiving ACE inhibitors before admission were less likely to
present with ruptured AAA (odds ratio [OR], 0.82; 95% confidence interval
[CI], 0.74 to 0.97) compared with those who did not receive ACE inhibi-
tors. Multiple adjustments, including those for demographic characteristics,
comorbidities, risk factors for rupture, measures of health care use, contra
indications to ACE inhibitors, and aneurysm screening yielded similar results
(OR, 0.83; 95% CI, 0.73 to 0.95). Similar findings were noted in subgroups
at high risk for rupture, including hypertensive patients and those patients
75 years of age. No protective associations were noted with other antihy-
pertensive medications including -blockers (OR, 1.02; 95% CI, 0.89 to
1.17), -blockers (OR, 1.15; 95% CI, 0.86 to 1.54), angiotensin receptor
blockers (OR, 1.24; 95% CI, 0.71 to 2.18), calcium channel blockers (OR,
1.01, 95%CI 0.89 to 1.14), or thiazide diuretics (OR, 0.91; 95%CI, 0.78 to
1.07).
Comment: The study has several important limitations. Healthier
patients, perhaps with a lower risk of rupture, may have been more likely to
receive ACE inhibitors. Of most importance is that the authors did not
control for AAA size, and certainly diameter is a significant predictor of AAA
rupture. In addition, AAAs grow for a long period of time, and no analysis
was done for the length of time the patients were on ACE inhibitors. The
data are interesting but insufficient to recommend routine treatment of AAA
patients with ACE inhibitors at this time.
30 day results from the SPACE trial of stent-protected angioplasty
versus carotid endarterectomy in symptomatic patients: A randomised
non-inferiority trial
The SPACE Collaborative Group. Lancet 2006;368:1239-47.
Conclusion: Short-term results do not support widespread use of
carotid artery stenting for treatment of symptomatic carotid artery stenosis.
Summary: This was a prospective, randomized clinical trial from 35
centers conducted in German, Austria, and Switzerland in which 1200
patients with symptomatic carotid artery stenosis were randomly assigned to
receive either carotid artery stenting (n  605) or carotid endarterectomy
(n 595). Ipsilateral ischemic stroke or death from the time of randomiza-
tion to 30 days after the procedure were primary end points for the study.
The noninferiority margin was defined as2.5%, and this was on the basis of
an expected event rate of 5%. An intention-to-treat analysis was used.
The study analyzed 1183 patients. The primary end point was achieved
in 6.84% in patients treated with carotid artery stents, and 6.34% in patients
treated with carotid endarterectomy, an absolute difference of 0.51% (95%
confidence interval [CI] 1.89% to 2.91%). In determining noninferiority,
the one-sided P value for noninferiority was 0.09. If only patients treated per
protocol were analyzed, and the 72 patients who were not treated, changed
treatment groups, or were treated 14 days after randomization were
excluded, the final outcome event rate was 6.95% in the carotid artery
stenting group and 5.64% in the carotid endarterectomy group (absolute
difference 1.32%, 95% CI 1.1% to 3.76%).
Comment: The study was unable to prove carotid stenting was not
inferior to carotid endarterectomy. The study does not prove that carotid
artery stenting is inferior to carotid endarterectomy. However, for all out-
come analyses, there appeared to be a tendency towards better results with
endarterectomy. The author’s conclusion that “the results of this trial (do)
not justify the widespread use of carotid artery stenting for treatment of
carotid artery stenosis”, is consistent with the recently published French trial
in the New England Journal of Medicine. In that trial, carotid stenting was
inferior to carotid endarterectomy in patients of symptomatic carotid steno-
sis. The results of the SPACE trial are also consistent with two large recently
published meta-analyses (Stroke 2005;36:905-11 and Neurosurgery 2005;
56:1171-79).
Identification of patients at low risk for recurrent venous thromboem-
bolism by measuring thrombin generation
Hron G, Kollars N, Binder BR. JAMA 2006;296:397-402.
Conclusion: Patients at low risk for recurrent venous thromboembo-
lism (VTE) can be identified by measurement of thrombin generation.
Summary: Patients with VTE are often investigated for thrombophilia
risk factors. A large number of potential thrombophilia risk factors make this
investigation complex and expensive. The authors sought to determine
whether the risk of recurrent VTE could be assessed by a global coagulation
assay that measures thrombin generation.
This was a cross-sectional, prospective cohort study of 914 patients. All
patients had a spontaneous VTE. They were followed up for average of 47
months after discontinuation of oral anticoagulant therapy. The study
period was from July 1992 to July 2005. A commercially available assay
system was used to determine thrombin generation. Excluded patients
included those with secondary VTE, those with recurrent VTE, or those
with a known thrombophilia risk factor such as antithrombin III, protein C
or protein S deficiencies, or the presence of lupus anticoagulant, cancer, or
pregnancy. The primary outcome measure was an objectively documented
episode of recurrent VTE.
VTE recurred in 100 patients (11%). Patients without recurrent VTE
generated less thrombin than those with recurrent VTE (349.2 108 nN vs
415  110.5 nN, P  .001). In patients with thrombin generation values
between 400 nN and 300 nN, the relative risk of recurrence compared to
patients with thrombin generations 400 nN was 0.42 (95% confidence
interval [CI], 0.26 to 0.67, P .001). In patients with measured thrombin
generations 300nN, relative risk was 0.37 (95% CI, 0.21 to 0.66, P 
.001). Over 4 years, the probability of VTE recurrence in patients with
thrombin generation 400 nN was 6.5% (95% CI, 4.0% to 8.9%). In those
patients with thrombin generation values 400, the probability of VTE
recurrence was 20.0% (95% CI, 14.9% to 25.1%, P  .001). Patients with
thrombin generation 400 nN had a 60% lower recurrence of VTE than
those with greater values of thrombin generation (relative risk, 0.40; 95%CI,
0.27 to 0.60, P  .001.
Comment:There are data to suggest that patients with idiopathic VTE
benefit from longer periods of anticoagulation than those with VTE and a
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